Top of this page
Skip navigation, go straight to the content

ucb-usa.com Newsroom UCB U.S. News

Categories

  • UCB Participates on NIH Task Force

    Posted by Katelyn Snider, U.S. Communications and Public AffairsPRGLAC_Icon_1280x960

    Last year, the Secretary of Health and Human Services (HHS) appointed UCB’s Kristi Lengyel, Director of U.S. Patient Advocacy, to the National Institutes of Health (NIH) Task Force on Research Specific to Pregnant and Lactating Women (PRGLAC).

    Read more

  • Like
  • Press Release: UCB announces BRIVIACT® (brivaracetam) now approved by FDA to treat partial-onset (focal) seizures in pediatric epilepsy patients

    Briviact_1280x960_Logo

    • BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures.
    • Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic dose from day one.
    • Pediatric epilepsy is the most common, serious neurological disorder among children and young adults, thought to affect nearly 470,000 children in the U.S.,1, 2
    • Indication comes less than 2 years after the launch of BRIVIACT in the U.S., building on existing adult monotherapy and adjunctive therapy indications, and broadening clinical application for UCB’s newest anti-epilepsy drug.


    Read more

  • Like
  • Disease Spotlight: 5 Things to Know About Osteoporosis

    Posted by Katelyn Snider, U.S. Communications and Public Affairs4_5_Untreated.gif

    By the time you finish reading the title of this post, a fragility fracture due to osteoporosis has occurred. It is estimated that a fragility fracture occurs every 3 seconds— totaling nearly 9 million fractures annually, worldwide. In the U.S. alone, fragility fractures are responsible for approximately 500,000 hospitalizations, 800,000 emergency room visits, and 180,000 nursing home placements each year.

    Read more

  • Like
  • UCB Engages Community on how Service Dogs Help People with Epilepsy

    Posted by Katelyn Snider, U.S. Communications and Public AffairsCanine_Assistants_1280x960

    This spring, UCB engaged the Atlanta community at the 2018 Atlanta Science Festival with a booth called “How the Canine Mind Helps People with Severe Diseases.” The festival is a two-week celebration of science offering more than 100 events at locations throughout metro Atlanta. UCB participated at the expo event held in Piedmont Park on March 24.

    Read more

  • Like
  • UCB’s Dr. Luiz Miguel Camargo, Dedicated to Finding Cures

    Posted by Katelyn Snider, U.S. Communications and Public Affairsluiz_BTS_1280x960

    Luiz Miguel Camargo, Ph.D., UCB’s Director of Innovation Networks, was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign talking about his work and dedication to advancing science to find solutions.

    Read more

  • Like
  • UCB’s Dr. Victor Sloan Shares His Commitment to Go Boldly

    Posted by Katelyn Snider, U.S. Communications and Public AffairsVictor_BTS_1280x960

    Dr. Victor Sloan, UCB’s VP & Development Strategy Lead (immunology), was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign. Learn more about Dr. Sloan’s work and his motivation to find groundbreaking solutions.

    Read more

  • Like
  • UCB’s Commitment in Neurology

    Posted by Mike Davis, Head of U.S. Neurology Patient Value UnitResearch_for_blog_post_4.20.18_1280x960Today, we announced an exciting addition to UCB’s epilepsy pipeline with an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261),1 an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.

    Read more

  • Like
  • Press Release: UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen

    blog_announcement_crop_002
    UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen

    Read more

  • Like
  • UCB Celebrates Parkinson’s Disease Awareness Month

    Posted by Katelyn Snider, U.S. Communications and Public Affairsbigger Parkinsons Stat with Logo  source NEW WITH LOGO.gif

    April is Parkinson’s Awareness Month. To honor those living with Parkinson’s disease (PD), we’re spreading awareness about the disease and sharing some of our favorite stories of inspiration.

    Read more

  • Like
  • Welcome to UCB USA

    Posted by Allyson Funk, Head of U.S. Communications and Public Relations

    Blog_Photo_1280x960

    As the U.S. affiliate of UCB, a global biopharmaceutical company, we are excited to be relaunching UCB-USA.com and a blog with news on UCB in the U.S.

    Read more

  • Like